Sophia Genetics

From Wikipedia, the free encyclopedia
Sophia Genetics
TypePublic (since 2021)
Nasdaq: SOPH
IndustryBiotechnology
Founded2011
Headquarters
Lausanne, Switzerland
Boston, United States
Area served
Worldwide
Key people
  • Jurgi Camblong (CEO & founder)
  • Bram Goorden (COO)
  • Lara Hashimoto (CBO)
  • Damien Lapray (Global head of sales, Healthcare division)
  • Valentin Matillon (CFO)
  • Philippe Menu (CMO)
  • Sergei Yakneen (CTO)
  • Zhenyu Xu (CSO)
  • Manuela Valente (CPO)
ProductsSophia AI platform
Servicesgenomic and radiomic analysis
Number of employees
300+
SubsidiariesInteractive Biosoftware
Websitewww.sophiagenetics.com

SOPHiA GENETICS is an American Swiss biotechnology company with its headquarters in Lausanne and Boston.[1][2] [3][4] It provides genomic and radiomic analysis for hospitals.[5][6] The company was ranked among the 50 smartest companies by the MIT Technology Review in 2017.[7] The company went public on the Nasdaq in 2021, floating at $1.1B.[8]

History[]

Sophia Genetics was co-founded by Jurgi Camblong, Pierre Hutter, and Lars Steinmetz in 2011 as start-up at École Polytechnique Fédérale de Lausanne (EPFL).

In September 2017, the company introduced an analytical software platform, which helps to interpret circulating tumor DNA and circulating tumour cells in blood, urine, cerebral spinal fluid and other liquid samples.[9][10]

In 2018, the company set up its first research and development center in France and made acquisition of a France-based molecular biology and genetic analytics software development company, Interactive Biosoftware.[11][12]

In 2020, the company appointed Troy Cox, former board of directors member, as its new chairman,[13][14] and Lara Hashimoto as chief business officer.[15]

Funding[]

In September 2013, as part of a Series A round of funding, Sophia Genetics received $3 million for its medical software platform. The funding round was led by a London-based venture capital firm Balderton Capital with participation from Invoke Capital, and Belgian pharmaceutical entrepreneur Marc Coucke.

In 2014, as part of a Series B round of funding, the company raised $13.75 million from Swisscom and Endeavour Vision.[16]

In December 2015, as part of a Series C round of funding, Sophia Genetics raised $15 million from Omega Pharma founder and healthcare scion Marc Coucke.[17]

In September 2017, as part of a Series D round of funding, the company received $30 million from UK-based VC firm Balderton Capital, 360 Capital Partners, and existing investors including Invoke Capital and Alychlo.[18]

In January 2019, as part of a Series E round of funding, the company raised $77 million. The round was led by Generation Investment Management and included early backers Idinvest Partners, Balderton Capital, and Alychlo.[1][19][20]

In October 2020, as part of a Series F round of funding, the company raised $110 million. The round was led by aMoon a health-tech & life sciences venture fund based in Israel, and Hitachi Ventures, a venture arm of Japanese Hitachi Group. [21]

Partnership[]

Sophia Genetics formed partnerships with Integrated DNA Technologies and Paragon Genomics, next-generation sequencing (NGS) assay development company, to provide COVID-19 test kits[22][23]

The company also partners with Illumina and MGI, a subsidiary of BGI Group, to enable their users to access SOPHiA Platform for data analysis and interpretation.[24][25]

References[]

  1. ^ Jump up to: a b Lomas, Natasha (4 January 2019). "Sophia Genetics bags $77M Series E, with 850+ hospitals signed up to its 'data-driven medicine'". TechCrunch.
  2. ^ "SOPHiA GENETICS - Contact". www.sophiagenetics.com. Retrieved 2020-10-05.
  3. ^ Murgia, Madhumita (2015-11-29). "Data-driven medicine: SOPHiA GENETICS becomes largest clinical genomics network". The Daily Telegraph. Retrieved 2019-07-08.
  4. ^ "Swiss data analytics company SOPHiA GENETICS could be Switzerland's next unicorn". TechCrunch. Retrieved 2019-07-08.
  5. ^ "An Interview with SOPHiA GENETICS: STS and the CE-IVD Designation". Front Line Genomics. 2019-04-16.
  6. ^ Gaskell, Adi; Wall, Matthew (2018-04-27). "How knowing your genetic code could lengthen your life". BBC. Retrieved 2019-07-08.
  7. ^ "The 50 Smartest Companies of 2017 might not be what you think". MIT Technology Review. Retrieved 2019-07-08.
  8. ^ Kilgore, Tomi. "SOPHiA Genetics set to go public at a $1.1 billion valuation". MarketWatch. Retrieved 2021-08-19.
  9. ^ "Swiss company sets up US headquarters in Boston - The Boston Globe". The Boston Globe. 24 September 2018.
  10. ^ Sweeney, Kate (24 September 2018). "Genome analysis ace opens in Boston Massachusetts | Business Weekly | Technology News | Business news | Cambridge and the East of England". Business Weekly.
  11. ^ Lerivrain, Hélène (25 April 2018). "La biotech suisse Sophia Genetics continue d'investir et s'installe au Pays basque". La Tribune (in French).
  12. ^ Chavanne, Yannick (18 June 2018). "Sophia Genetics rachète un spécialiste mondial de l'exploration de variations génomiques". ICT Journal (in French).
  13. ^ Hale, Conor (21 February 2020). "Sophia Genetics taps ex-Foundation Medicine CEO as chairman". FierceBiotech.
  14. ^ "Sophia Genetics changera de président début mars". AGEFI (in French). 20 February 2020.
  15. ^ Credi, Mer (8 April 2020). "Sophia Genetics élargit son équipe de direction". AGEFI (in French).
  16. ^ "Sophia Genetics Raises $13.8M in Private Financing Round". GenomeWeb. 8 July 2014.
  17. ^ "Europe's leading entrepreneurs leads Series C Round in Sophia Genetics". Venture Lab. 16 December 2015.
  18. ^ Lomas, Natasha (13 September 2017). "Balderton joins $30M Series D for big data biotech platform play, Sophia Genetics". TechCrunch.
  19. ^ Wise, James (4 January 2019). "Sophia Genetics announces new $77M funding round". Medium (website).
  20. ^ O'brien, Chris (4 January 2019). "Swiss startup Sophia Genetics raises $77 million to expand its AI diagnostic platform in the U.S." VentureBeat.
  21. ^ "Sophia Genetics raises $110M to fuel global data platform expansion".
  22. ^ "IDT, SOPHiA Genetics Broaden Partnership to Clinical-Grade Technologies". Clinical OMICs - Molecular Diagnostics in Precision Medicine. 17 January 2020.
  23. ^ "Sophia Genetics, Paragon Genomics Team on SARS-CoV-2 Testing". Clinical OMICs - Molecular Diagnostics in Precision Medicine. 26 March 2020.
  24. ^ "Illumina, Sophia Genetics to Comarket NGS Solutions for Clinical Dx". GenomeWeb.
  25. ^ "Sophia Genetics to Provide Access to Genomic Analysis Platform to MGI Customers". GenomeWeb.

External links[]

Retrieved from ""